Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC

Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of...

Full description

Saved in:
Bibliographic Details
Published inBMC medical genomics Vol. 12; no. 1; pp. 67 - 12
Main Authors Bao, Jiarong, Li, Man, Liang, Shumei, Yang, Yunchu, Wu, Jingfang, Zou, Qingqing, Fang, Shun, Chen, Size, Guo, Linlang
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 22.05.2019
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs.
AbstractList Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research.BACKGROUNDChemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research.In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction.METHODSIn this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction.In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs.RESULTSIn total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs.We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs.CONCLUSIONSWe screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs.
Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs.
Background Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. Methods In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. Results In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. Conclusions We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs. Keywords: Small cell lung cancer, Chemoresistance, Super enhancer
Abstract Background Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. Methods In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. Results In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. Conclusions We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs.
Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs.
Background Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. Methods In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. Results In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. Conclusions We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs.
ArticleNumber 67
Audience Academic
Author Yang, Yunchu
Fang, Shun
Guo, Linlang
Wu, Jingfang
Chen, Size
Li, Man
Zou, Qingqing
Liang, Shumei
Bao, Jiarong
Author_xml – sequence: 1
  givenname: Jiarong
  surname: Bao
  fullname: Bao, Jiarong
– sequence: 2
  givenname: Man
  surname: Li
  fullname: Li, Man
– sequence: 3
  givenname: Shumei
  surname: Liang
  fullname: Liang, Shumei
– sequence: 4
  givenname: Yunchu
  surname: Yang
  fullname: Yang, Yunchu
– sequence: 5
  givenname: Jingfang
  surname: Wu
  fullname: Wu, Jingfang
– sequence: 6
  givenname: Qingqing
  surname: Zou
  fullname: Zou, Qingqing
– sequence: 7
  givenname: Shun
  surname: Fang
  fullname: Fang, Shun
– sequence: 8
  givenname: Size
  surname: Chen
  fullname: Chen, Size
– sequence: 9
  givenname: Linlang
  orcidid: 0000-0002-1859-7592
  surname: Guo
  fullname: Guo, Linlang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31118037$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1rFDEYhQep2A_9Ad7IgDd6MTXJTCaTG6EsfiwsCFavQyZ5M5Mym6xJptp_b6Zba7eI5CIvyXNOyOGcFkfOOyiKlxidY9y17yImnKAKYV4hmgf-pDjBjNKqY7w5ejAfF6cxXiHUIsrxs-K4xlmPanZSmLVLMASZQJejHcYqjcHPw7ibUymdnG6ijaXV4JI1FmIZ5x2EEtwonYIQSxmjV_ZW_tOmsVQjbH2ArEoLUVpXXq42q-fFUyOnCC_u9rPi-8cP31afq82XT-vVxaZSlDepwrRtNO5qhgk2TPKuN7ViYChHsgfSddAbxWtDgPW454rSXjLdS05Uo4CZ-qxY7321l1diF-xWhhvhpRW3Bz4MQoZk1QSC1pJQIrOTZA3leUIaal0z3bGclM5e7_deu7nfglY5gyCnA9PDG2dHMfhr0dKaEEqzwZs7g-B_zBCT2NqoYJqkAz9HQUhNMGpJQzL6-hF65eeQ81-ohjDKOMZ_qUHmD1hnfH5XLabignZtrgClXabO_0HlpWFrVW6Qsfn8QPD2QJCZBL_SIOcYxfry6yH76mEo92n8aVQG8B5QwccYwNwjGImltWLfWpFbK5bWCp417JFG2SST9UuudvqP8jekNvB4
CitedBy_id crossref_primary_10_1038_s42003_025_07804_7
crossref_primary_10_3390_ijms23169154
crossref_primary_10_1371_journal_ppat_1009311
crossref_primary_10_1002_advs_202409050
crossref_primary_10_1016_j_celrep_2021_110109
crossref_primary_10_1002_1878_0261_12693
crossref_primary_10_3389_fphar_2022_1071365
crossref_primary_10_1016_j_canlet_2024_217129
crossref_primary_10_1089_gtmb_2023_0280
crossref_primary_10_1016_j_mam_2023_101205
crossref_primary_10_3390_cancers14081978
crossref_primary_10_1016_j_celrep_2020_107532
Cites_doi 10.1016/j.cell.2016.12.013
10.1038/nrg3496
10.1146/annurev.genet.37.110801.143851
10.1186/gb-2008-9-9-r137
10.18632/oncotarget.11057
10.1016/S0140-6736(11)60165-7
10.1016/j.cell.2013.03.035
10.1038/s41467-018-03279-9
10.1016/j.cell.2013.02.014
10.1016/j.trecan.2017.03.006
10.1186/1476-4598-6-31
10.1126/science.aar3958
10.2174/1566524016666151222144656
10.1038/s41568-018-0005-8
10.1093/bioinformatics/btn542
10.1038/nm.3665
10.1038/ng.3167
10.1016/j.cell.2014.02.009
10.1126/scisignal.2001946
10.1038/ng.3605
10.1016/j.leukres.2011.08.006
10.1016/j.cub.2010.06.070
10.1016/j.cell.2013.03.036
10.1016/j.cell.2013.09.053
10.1158/0008-5472.CAN-16-2874
10.1038/onc.2012.306
10.1016/j.ccell.2018.03.022
10.1186/gb-2007-8-2-r24
ContentType Journal Article
Copyright COPYRIGHT 2019 BioMed Central Ltd.
2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s). 2019
Copyright_xml – notice: COPYRIGHT 2019 BioMed Central Ltd.
– notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s). 2019
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7X7
7XB
88E
8AO
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
7X8
5PM
DOA
DOI 10.1186/s12920-019-0520-9
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection (subscription)
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



MEDLINE

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1755-8794
EndPage 12
ExternalDocumentID oai_doaj_org_article_53a252ae7ba74592ae0de3d37d87006d
PMC6532255
A586520558
31118037
10_1186_s12920_019_0520_9
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
  grantid: 81772458
– fundername: ;
  grantid: 81572244
– fundername: ;
  grantid: 2015A030311028
– fundername: ;
  grantid: 2017A030313468
GroupedDBID ---
0R~
23N
2WC
53G
5GY
5VS
6J9
7X7
88E
8AO
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
ISR
ITC
KQ8
LK8
M1P
M48
M7P
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
~8M
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
RC3
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c594t-1564d1837121f7a98bf3c7ef590abe288ebfc93f2e7b1b9c55ba7dba92c4ce7f3
IEDL.DBID 7X7
ISSN 1755-8794
IngestDate Wed Aug 27 01:32:12 EDT 2025
Thu Aug 21 14:11:46 EDT 2025
Fri Jul 11 14:13:14 EDT 2025
Fri Jul 25 19:22:12 EDT 2025
Tue Jun 17 21:06:09 EDT 2025
Tue Jun 10 20:29:15 EDT 2025
Fri Jun 27 04:59:05 EDT 2025
Thu Jan 02 22:59:27 EST 2025
Tue Jul 01 02:55:34 EDT 2025
Thu Apr 24 22:51:55 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Small cell lung cancer
Chemoresistance
Super enhancer
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c594t-1564d1837121f7a98bf3c7ef590abe288ebfc93f2e7b1b9c55ba7dba92c4ce7f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-1859-7592
OpenAccessLink https://www.proquest.com/docview/2242757911?pq-origsite=%requestingapplication%
PMID 31118037
PQID 2242757911
PQPubID 55237
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_53a252ae7ba74592ae0de3d37d87006d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6532255
proquest_miscellaneous_2232106242
proquest_journals_2242757911
gale_infotracmisc_A586520558
gale_infotracacademiconefile_A586520558
gale_incontextgauss_ISR_A586520558
pubmed_primary_31118037
crossref_primary_10_1186_s12920_019_0520_9
crossref_citationtrail_10_1186_s12920_019_0520_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-05-22
PublicationDateYYYYMMDD 2019-05-22
PublicationDate_xml – month: 05
  year: 2019
  text: 2019-05-22
  day: 22
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC medical genomics
PublicationTitleAlternate BMC Med Genomics
PublicationYear 2019
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References J Tower (520_CR2) 2004; 38
SC Tripathi (520_CR13) 2017; 77
JE Bradner (520_CR27) 2017; 168
L Adesso (520_CR28) 2013; 32
J Hu (520_CR29) 2016; 16
M Corvaisier (520_CR20) 2016; 7
M Levine (520_CR26) 2010; 20
TS Huang (520_CR21) 2007; 6
HY Shin (520_CR8) 2018; 41
JP van Meerbeeck (520_CR1) 2011; 378
D Hay (520_CR17) 2016; 48
D Herranz (520_CR5) 2014; 20
M Levine (520_CR25) 2014; 157
RW Robey (520_CR14) 2018; 18
WA Whyte (520_CR23) 2013; 153
A Kuhnl (520_CR22) 2011; 35
J Lovén (520_CR7) 2013; 153
Y Zhang (520_CR10) 2008; 9
M Rojo de la Vega (520_CR12) 2018; 34
D Hnisz (520_CR3) 2013; 155
S Pott (520_CR4) 2015; 47
S Sengupta (520_CR15) 2017; 3
H Stower (520_CR9) 2013; 14
J Huang (520_CR16) 2018; 9
A Brozzi (520_CR11) 2008; 24
TI Lee (520_CR24) 2013; 152
S Gupta (520_CR18) 2007; 8
BR Sabari (520_CR6) 2018; 361
S Ganesan (520_CR19) 2011; 4
References_xml – volume: 168
  start-page: 629
  issue: 4
  year: 2017
  ident: 520_CR27
  publication-title: Cell
  doi: 10.1016/j.cell.2016.12.013
– volume: 14
  start-page: 367
  issue: 6
  year: 2013
  ident: 520_CR9
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg3496
– volume: 38
  start-page: 273
  year: 2004
  ident: 520_CR2
  publication-title: Annu Rev Genet
  doi: 10.1146/annurev.genet.37.110801.143851
– volume: 9
  start-page: R137
  issue: 9
  year: 2008
  ident: 520_CR10
  publication-title: Genome Biol
  doi: 10.1186/gb-2008-9-9-r137
– volume: 7
  start-page: 56699
  issue: 35
  year: 2016
  ident: 520_CR20
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.11057
– volume: 378
  start-page: 1741
  issue: 9804
  year: 2011
  ident: 520_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60165-7
– volume: 153
  start-page: 307
  issue: 2
  year: 2013
  ident: 520_CR23
  publication-title: Cell
  doi: 10.1016/j.cell.2013.03.035
– volume: 9
  start-page: 943
  issue: 1
  year: 2018
  ident: 520_CR16
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-03279-9
– volume: 152
  start-page: 1237
  issue: 6
  year: 2013
  ident: 520_CR24
  publication-title: Cell
  doi: 10.1016/j.cell.2013.02.014
– volume: 3
  start-page: 269
  issue: 4
  year: 2017
  ident: 520_CR15
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2017.03.006
– volume: 6
  start-page: 31
  year: 2007
  ident: 520_CR21
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-6-31
– volume: 41
  start-page: 506
  issue: 6
  year: 2018
  ident: 520_CR8
  publication-title: Mol Cell
– volume: 361
  start-page: eaar3958
  issue: 6400
  year: 2018
  ident: 520_CR6
  publication-title: Science (New York, NY)
  doi: 10.1126/science.aar3958
– volume: 16
  start-page: 70
  issue: 1
  year: 2016
  ident: 520_CR29
  publication-title: Curr Mol Med
  doi: 10.2174/1566524016666151222144656
– volume: 18
  start-page: 452
  issue: 7
  year: 2018
  ident: 520_CR14
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-018-0005-8
– volume: 24
  start-page: 2918
  issue: 24
  year: 2008
  ident: 520_CR11
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btn542
– volume: 20
  start-page: 1130
  issue: 10
  year: 2014
  ident: 520_CR5
  publication-title: Nat Med
  doi: 10.1038/nm.3665
– volume: 47
  start-page: 8
  issue: 1
  year: 2015
  ident: 520_CR4
  publication-title: Nat Genet
  doi: 10.1038/ng.3167
– volume: 157
  start-page: 13
  issue: 1
  year: 2014
  ident: 520_CR25
  publication-title: Cell
  doi: 10.1016/j.cell.2014.02.009
– volume: 4
  start-page: pe15
  issue: 166
  year: 2011
  ident: 520_CR19
  publication-title: Sci Signal
  doi: 10.1126/scisignal.2001946
– volume: 48
  start-page: 895
  issue: 8
  year: 2016
  ident: 520_CR17
  publication-title: Nat Genet
  doi: 10.1038/ng.3605
– volume: 35
  start-page: 1585
  issue: 12
  year: 2011
  ident: 520_CR22
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2011.08.006
– volume: 20
  start-page: R754
  issue: 17
  year: 2010
  ident: 520_CR26
  publication-title: Curr Biol
  doi: 10.1016/j.cub.2010.06.070
– volume: 153
  start-page: 320
  issue: 2
  year: 2013
  ident: 520_CR7
  publication-title: Cell
  doi: 10.1016/j.cell.2013.03.036
– volume: 155
  start-page: 934
  issue: 4
  year: 2013
  ident: 520_CR3
  publication-title: Cell
  doi: 10.1016/j.cell.2013.09.053
– volume: 77
  start-page: 4414
  issue: 16
  year: 2017
  ident: 520_CR13
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-2874
– volume: 32
  start-page: 2848
  issue: 23
  year: 2013
  ident: 520_CR28
  publication-title: Oncogene
  doi: 10.1038/onc.2012.306
– volume: 34
  start-page: 21
  issue: 1
  year: 2018
  ident: 520_CR12
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.03.022
– volume: 8
  start-page: R24
  issue: 2
  year: 2007
  ident: 520_CR18
  publication-title: Genome Biol
  doi: 10.1186/gb-2007-8-2-r24
SSID ssj0060591
Score 2.283357
Snippet Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE)...
Background Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super...
Abstract Background Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 67
SubjectTerms Analysis
Bioinformatics
Biological response modifiers
Cancer
Cancer research
Cancer therapies
Care and treatment
Cell Line, Tumor
Chemoresistance
Chemotherapy
Chromatin
Computational Biology
CRISPR-Cas technology
Deoxyribonucleic acid
Disease
DNA
Drug resistance
Drug Resistance, Neoplasm - genetics
Enhancer Elements, Genetic - genetics
Enhancers
Forkhead protein
Foxp1 protein
Gene amplification
Gene expression
Gene regulation
Genetic aspects
Genomes
High-Throughput Nucleotide Sequencing
High-throughput screening (Biochemical assaying)
Humans
Immunoprecipitation
Interferon
Interferon regulatory factor
Interferon regulatory factor 1
Leukemia
Lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Noncoding DNA
Polymerase chain reaction
Regulatory sequences
Reverse transcription
RNA
RNA interference
RNA polymerase
RNA sequencing
RNA-mediated interference
Sequence Analysis, RNA
Small cell lung cancer
Small cell lung carcinoma
Small Cell Lung Carcinoma - genetics
Small Cell Lung Carcinoma - pathology
Sp1 protein
Super enhancer
Therapeutic applications
Transcription (Genetics)
Transcription factors
Transcription Factors - metabolism
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KL-G31lCiCIIRr06RJHs_F4048HzwP7i2k-fAWju6y3f7_zrTZZYugL76VzYS285vMTLaT3xDyIYWoJPcVM9o5JkyEq0YaFkLrghI-ifFQ2OX35vxafL2RNwetvrAmbKIHnhR3ImvHJXdRtU4JaeCqDLEOtQpgaWUT0PtCzNttpiYfDDm6qfI3zEo3J32FTZlg22wY1n0wM4tCI1n_ny75ICbN6yUPAtDZI_IwZ470dHrix-Re7J6Q-5f52_hTki52zA-BIgkxyy141sOWukw9Qpdhqg6KPe2HddzQ2N0i7pueugwUTMc_ZymgiUW4PSaYIEGXHb1afFs8I9dnX34uzlnuosC8NGLLkA0mwMJVFa-Scka3qfYqJmlK10audWyTN3XioOKqNV5K0DQgZbgXPqpUPydH3aqLLwkNrRTRlalxtRC-CaaM2slkTIypTaIsSLnTqvWZYhw7XdzZcauhGzsBYQEIi0BYU5BP-ynriV_jb8KfEaq9IFJjjz-AwdhsMPZfBlOQ9wi0RfKLDqtrfrmh7-3F1Q97KnUDN5JSF-RjFkoreAPv8mEF0APyZc0kj2eSsDr9fHhnTzZ7h95C2sSVVBBnCvJuP4wzseKti6sBZfB0FZ7eKciLyfz2711XSNxXq4KomWHOFDMf6Za3I3d4I9GDy1f_Q5OvyQM-LSnG-TE52m6G-AZStG37dlyNvwFVpzpc
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA_nCeKL-G31lCiCIFTbNGmaB5Fz8bgT1wfPhXsLaT7uFo7uut0F_e-dadNyxePeymZCm_xmMpPN5DeEvA3OS8FsnqrKmJQrD0-lUKlztXGS28C7S2HzH-Xxgn87E2d7ZChvFSewvXZrh_WkFpvLD39-__0MBv-pM_iq_NjmWHIJNsUqxayOVN0it8ExSbTTOR8PFSBwV3k82Ly228Q1dQz-_6_TVxzVNInyilc6uk_uxXCSHvb4PyB7vnlI7szjgfkjEk4GOghHkZk4jXV51rstNZGPhC5dnzLkW9ru1n5DfXOByrBpqYnoQXf8x5YCxJiZ22LUCRJ02dDT2ffZY7I4-vprdpzG0gqpFYpvU6SIcWDNMmd5kEZVdSis9EGozNSeVZWvg1VFYF7Wea2sELWRAJ9illsvQ_GE7Derxj8j1NWCe5OF0hSc29KpzFdGBKW8D3XgWUKyYVa1jbzjWP7iUnf7j6rUPRAagNAIhFYJeT92WfekGzcJf0GoRkHky-5-WG3OdTQ_LQrDBDMwGiO5UPCUOV-4QjpYr7LSJeQNAq2REaPBlJtzs2tbfXL6Ux-KqoQXCVEl5F0UCisYgTXxBgPMA5JoTSQPJpJgsnbaPOiTHjReQyzFpJDgfBLyemzGnpgG1_jVDmXwyhVe6UnI0179xnEXObL5FTIhcqKYk4mZtjTLi45QvBS4rIvnN3_WC3KX9caSMnZA9rebnX8JEdm2ftXZ2T8okjTG
  priority: 102
  providerName: Scholars Portal
Title Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC
URI https://www.ncbi.nlm.nih.gov/pubmed/31118037
https://www.proquest.com/docview/2242757911
https://www.proquest.com/docview/2232106242
https://pubmed.ncbi.nlm.nih.gov/PMC6532255
https://doaj.org/article/53a252ae7ba74592ae0de3d37d87006d
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZbC2MvY_e564I2BoOBqC1LlvU00tDShqWMZoW8CVmXNjCcLI7_f3VsJasZ9MU21hG29Okc3Y6-g9BXb53g1GRElloTJl14Krgk1lbaCmY86w6Fza6Kixs2XfBFXHBrolvlziZ2htquDKyRn4Suhgougm7-WP8lEDUKdldjCI2n6BCoy8ClSyz2E64wUpdZ3MnMyuKkySA0U5g8SwLeH0QO-qKOsv9_w_ygZxp6TT7ohs5fohdx_IjHPeCv0BNXv0bPZnGH_A3ylzv-B4uBipjEQDzrdot1JCDBS9v7CLkGN-3abbCr7wD9TYN1hCtkhyVaHDAFV9wGhplBAi9rPJ_8nLxFN-dnvycXJMZSIIZLtiXACWOD-oqMZl5oWVY-N8J5LlNdOVqWrvJG5p46UWWVNJxXWgS8JDXMOOHzd-igXtXuA8K24szp1Bc6Z8wUVqau1NxL6ZyvPEsTlO5qVZlINA7xLv6obsJRFqoHQgUgFAChZIK-77Ose5aNx4RPAaq9IBBkdy9Wm1sV9U3xXFNOdSiNFozL8JRal9tc2GCg0sIm6AsArYACowYfm1vdNo26nF-rMS-L8CHOywR9i0J-FUpgdDyyEOoBWLMGkscDyaCjZpi8a08q2ohG_WvRCfq8T4ac4PdWu1ULMnDGCs7wJOh93_z25c4zoO_LRYLEoGEOKmaYUi_vOgbxgoMd50eP_9ZH9Jz2ykIoPUYH203rPoUh2LYadXo2Qofj8XQ-DffTs6tf16NuQSNcZ6y8ByTcNsg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwEviDuBAQaBkJCiJY4dxw8IbWVTy9oK7SLtzTi-bJVQWppWiD_Fb8SnccoipL3tLYqPk9jn5hMffwehd85YzohOY1EoFVNh_VXORGxMqQyn2tH1obDxJB-c0a_n7HwL_WnPwkBaZWsT14bazDT8I9_1roZwxr1ufp7_jKFqFOyutiU0GrE4sr9_-ZCt_jT84vn7npDDg9P-IA5VBWLNBF3GgI5ivCDzlKSOK1GULtPcOiYSVVpSFLZ0WmSOWF6mpdCMlYr7LxdEU225y_xzb6FtmvlQpoe29w8m345b2-9jA5GGvdO0yHfrFIpB-XBdxJBvEouO91sXCfjfFVzxhd08zSuO7_A-uhdWrHivEbEHaMtWD9HtcdiTf4TcsEWcMBjAj-NQ-me-WmIVIE_w1DRZSbbG9WpuF9hWlyBvixqrICC-O_wUxl6KIPm3hoWtp8DTCp_0R_3H6OxG5vkJ6lWzyj5D2JSMWpW4XGWU6tyIxBaKOSGsdaWjSYSSdlalDtDmUGHjh1yHOEUuG0ZIzwgJjJAiQh83XeYNrsd1xPvAqg0hQHKvb8wWFzJouGSZIowoPxrFKRP-KjE2Mxk33iQmuYnQW2C0BNCNCrJ6LtSqruXw5FjusSL3L2KsiNCHQORmfgRahUMSfh4Ap6tDudOh9FZBd5tbeZLBKtXynw5F6M2mGXpCpl1lZyuggVNdcGooQk8b8duMO0sBMDDjEeIdwexMTLelml6uMctzBp6DPb_-s16jO4PT8UiOhpOjF-guaRQnJmQH9ZaLlX3pF4DL8lXQOoy-37Si_wXNs3Hk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Integrated+high-throughput+analysis+identifies+super+enhancers+associated+with+chemoresistance+in+SCLC&rft.jtitle=BMC+medical+genomics&rft.au=Bao%2C+Jiarong&rft.au=Li%2C+Man&rft.au=Liang%2C+Shumei&rft.au=Yang%2C+Yunchu&rft.date=2019-05-22&rft.pub=BioMed+Central&rft.eissn=1755-8794&rft.volume=12&rft_id=info:doi/10.1186%2Fs12920-019-0520-9
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1755-8794&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1755-8794&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1755-8794&client=summon